Clinical trials: Co-Infection HIV-HCV
Hepatitis C, Chronic, HIV Infection
Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir
Hypothesis: the Telaprevir(TVR) plasma levels (750 mg q8h or 1125 mg/12h )will not be affected when co-administered with un-boosted Atazanavir (ATV) 200 mg q12h plus two analogues (NRTIs) in HCV/HIV-co-infected patients.
- Trial name
- NCT01818856
- Testing
- Ritonavir withdrawal, atazanavir 200 mg/12h, Telaprevir interactions
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
Human Immunodeficiency Virus-Infection
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.
- Trial name
- NCT01153269
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 8 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Abbott
HIV, Hepatitis C
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
HIV infection exerts a negative impact on the course of HCV infection. Co-infected individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared to those infected with HCV alone.
- Conditions
- HIV, Hepatitis C, Liver Fibrosis
- Trial name
- NCT01231685
- Testing
- Raltegravir, Ritonavir-boosted protease inhibitor
- Where
- 3 sites in Canada
- Volunteers
- 9 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV-1 Infection, HCV Infection
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or emtricitabine/rilpivirine/tenofovir…
- Trial name
- Co-STARs (NCT02707601)
- Testing
- E/C/F/TAF, F/R/TAF, LDV/SOF
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV Coinfection
Supporting Treatment Outcomes Among PWID
The goal of this study is to improve HCV care continuum outcomes for people who inject drugs (PWID), reduce potential onward transmission to others and improve HIV outcomes among those who are HIV/HCV coinfected.
- Trial name
- STOP-C (NCT04652804)
- Testing
- Low intensity HCV treatment adherence support, Medium intensity HCV treatment adherence support, High intensity HCV treatment adherence support
- Where
- India
- Volunteers
- 3,000 people
- Sponsor
- Johns Hopkins University
HIV Infections, Hepatitis C
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
This study will test the amount of anti-HIV drugs in the blood cells of HIV-infected patients who are also being treated for hepatitis C virus (HCV) infection.
- Trial name
- NCT00059358
- Testing
- Ribavirin plus interferon alfa-2b, Ribavirin, Peginterferon alfa-2b
- Where
- Puerto Rico
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV
HCV-HIV Co-infected Patient Cohort in Thailand
This is a study of HCV treatment using the standard regimen of pegylated-interferon plus ribavirin in HIV co-infected patients participating in the PHPT cohort study.
- Trial name
- NCT02247440
- Testing
- Peg-interferon + ribavirin under HIV physician supervision
- Where
- 5 sites in Thailand
- Volunteers
- 18 people
- Sponsor
- Institut de Recherche pour le Developpement
Hepatitis C, HIV Infections
Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.
- Trial name
- ART and HCV (NCT00545558)
- Testing
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Cincinnati
HIV, Hepatitis C
Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV
The ANRS CO13 HEPAVIH cohort is a prospective and multicentric cohort created in 2005 with the originality to cover two therapeutic domains of key importance, AIDS and hepatitis C.
- Trial name
- CO13Hepavih (NCT03324633)
- Volunteers
- 1,850 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, HIV
Control and Elimination Within Australia of Hepatitis C From People Living With HIV
The purpose of this study is to evaluate the feasibility of rapid scale-up of new hepatitis C (HCV) treatments, known as interferon-free Direct Acting Antiviral (DAA) drugs, and impact on the proportion of people with HCV within…
- Conditions
- Hepatitis C, HIV, HIV-HCV Coinfection
- Trial name
- CEASE (NCT02102451)
- Where
- 18 sites in Australia
- Volunteers
- 492 people
- Sponsor
- Kirby Institute
HCV Coinfection, HIV Infection
Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection
Primary Objective: To compare the impact of switching from efavirenz (EFV) plus two nucleoside analogs to rategravir (RAL) plus two nucleoside analogs versus keeping the same antiretroviral regimen on hepatic steatosis (HS) as…
- Trial name
- STERAL (NCT01900015)
- Testing
- Raltegravir, Efavirenz
- Where
- 10 sites in Spain
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Juan Macías
Hepatitis C Virus, Hiv Infections
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
This trial is designed to assess the safety, tolerability, pharmacokinetics and viral kinetics after multiple infusions of bavituximab in patients co-infected with HCV and HIV.
- Trial name
- NCT00503347
- Testing
- bavituximab
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Peregrine Pharmaceuticals
HIV Infection, Hepatitis C
A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
The purpose of this study is to determine whether a simplified lopinavir/ritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra (lopinavir/ritonavir)…
- Trial name
- NCT00121017
- Testing
- Kaletra (lopinavir/ritonavir), Sustiva (efavirenz), Truvada (emtricitabine/tenofovir disoproxil fumarate)
- Volunteers
- 200 people
- Sponsor
- Abbott
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
The purpose of this study is to assess the efficacy and safety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus-1 co-infection.
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- EXPEDITION-2 (NCT02738138)
- Testing
- ABT-493 coformulated with ABT-530
- Volunteers
- 153 people
- Sponsor
- AbbVie
HIV Infections
Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV
The purpose of this study is to compare the early virological response (EVR = undetectable [ribonucleic acid-hepatitis C virus] RNA-HCV or a reduction of > 2 log10) of patients with chronic hepatitis C coinfected with HIV treated…
- Trial name
- NCT00356486
- Testing
- Peginterferon alfa-2a, Ribavirin, epoetin-β, Peginterferon alfa-2a + Ribavirin for 12 weeks
- Where
- 12 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV, Hepatitis C
Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection
End-stage liver disease, predominantly due to hepatitis C virus (HCV) infection, is one of the leading causes of death in person living with HIV infection.
- Conditions
- HIV, Hepatitis C, Co-Infection
- Trial name
- NCT02294136
- Testing
- Prep-C, Educational Control
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatitis C, Human Immunodeficiency Virus
Dutch Acute HCV in HIV Study (DAHHS)
Prospective open label proof of concept feasibility interventional clinical trial in which 60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in addition to Standard Of Care Peginterferon +…
- Trial name
- DAHHS (NCT01912495)
- Testing
- Boceprevir
- Where
- 9 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- Erasmus Medical Center
Hepatitis C
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.
- Trial name
- NCT02032888
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 37 sites in United States
- Volunteers
- 238 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Hiv
Integrating HIV and Hepatitis C Screening in an Urban Emergency Department
This randomized controlled trial was implemented to evaluate the effect of integrating rapid Hepatitis C (HCV) testing into a pre-existing screening program for Human Immunodeficiency Virus (HIV) on HIV test acceptance and…
- Conditions
- Hepatitis C, Hiv, HIV/AIDS, HCV Coinfection
- Trial name
- NCT03252483
- Testing
- Bundled HCV/HIV Screening, HIV Screening
- Where
- United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- New York City Health and Hospitals Corporation
HIV Infection, HCV Coinfection
Folinic Acid: Supplementation and Therapy
Patients infected by HIV or HIV-HCV coinfected have higher survival due to the use of HAART, but survival is accompanied by increased morbidity and associated cardiovascular disease (CVD).
- Trial name
- FAST (NCT02810275)
- Testing
- Folinic Acid
- Volunteers
- 69 people
- Sponsor
- Hospital de Clinicas de Porto Alegre